# OnCo record dizal (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/dizal/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "dizal" ;
  schema:name "Dizal Pharmaceutical"@en ;
  schema:alternateName "Dizal Pharmaceuticals"@en, "Dizal (Jiangsu) Pharmaceutical Co., Ltd."@en, "迪哲医药"@en ;
  schema:description "Dizal is a Shanghai biotechnology company built on small-molecule kinase inhibitors: sunvozertinib for EGFR exon 20 insertion lung cancer and DZD8586, a dual LYN and BTK inhibitor in the phase 3 TAI-SHAN6 trial for relapsed chronic lymphocytic leukaemia."@en ;
  schema:url <https://onco.cc/companies/dizal/>, <https://www.dizalpharma.com/> ;
  schema:dateModified "2026-09-11"^^xsd:date ;
  schema:citation <https://www.dizalpharma.com/>, <https://clinicaltrials.gov/search?lead=Dizal> ;
  onco:tag "ctgov-sponsor" ;
  schema:addressCountry "CN" ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/cll/> ;
  onco:sections <https://onco.cc/fronts/targeted-therapy/> ;
  onco:drugs <https://onco.cc/drugs/sunvozertinib/>, <https://onco.cc/drugs/dzd8586/>, <https://onco.cc/drugs/golidocitinib/> ;
  onco:trials <https://onco.cc/trials/tai-shan6/>, <https://onco.cc/trials/nct05668988/>, <https://onco.cc/trials/nct05712902/>, <https://onco.cc/trials/nct03974022/>, <https://onco.cc/trials/nct07079475/>, <https://onco.cc/trials/nct07059650/>, <https://onco.cc/trials/nct07070440/>, <https://onco.cc/trials/nct06295432/>, <https://onco.cc/trials/nct07328217/>, <https://onco.cc/trials/nct07496229/>, <https://onco.cc/trials/nct06276283/>, <https://onco.cc/trials/nct07154264/>, <https://onco.cc/trials/nct06539182/> .